Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: University Hospital, Bonn
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hyperlipidemia|Hypercholesterolemia|Hyperlipoproteinemias
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
LIF293/95apoB | P3 |
Completed |
Hyperlipidemia|Hypercholesterolemia|Hyperlipoproteinemias |
1996-04-01 |